Prof. Dr. med. Michael Wiesener

Medizin 4

Transplantationszentrum

Prof. Dr. med. Michael Wiesener

Oberarzt, Facharzt für Innere Medizin und Nephrologie, Hypertensiologe (DHL)

Ulmenweg 18
91054 Erlangen

Gebäude
Internistisches Zentrum (INZ)

Einrichtungen
Medizin 4
Transplantationszentrum

michael.wiesener(at)uk-erlangen.de

Lebenslauf, Veröffentlichungen und Auszeichnungen

Publikationen

Protze J, Naas S, Krüger R, Stöhr C, Kraus A, Grampp S, Wiesener M, Schiffer M, Hartmann A, Wullich B, Schödel J: (2022) The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression. J Biol Chem. 2022;298(3):
Meng X, Lin Z, Cao S, Janowska I, Sonomoto K, Andreev D, Katharina K, Wen J, Knaup KX, Wiesener MS, Krönke G, Rizzi M, Schett G, Bozec A: (2022) Estrogen-mediated downregulation of HIF-1α signaling in B lymphocytes influences postmenopausal bone loss. Bone Res. 2022;10(1):
Wopperer FJ, Knaup KX, Stanzick KJ, Schneider K, Jobst-Schwan T, Ekici AB, Uebe S, Wenzel A, Schliep S, Schürfeld C, Seitz R, Bernhardt W, Gödel M, Wiesener A, Popp B, Stark KJ, Gröne HJ, Friedrich B, Weiß M, Basic-Jukic N, Schiffer M, Schröppel B, Huettel B, Beck BB, Genomics England Research Consortium , Sayer JA, Ziegler C, Büttner-Herold M, Amann K, Heid IM, Reis A, Pasutto F, Wiesener MS: (2022) Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases. Kidney Int. 2022;102(2): 405-420
Gwinner W, Karch A, Braesen JH, Khalifa AA, Metzger J, Naesens M, Van Loon E, Anglicheau D, Marquet P, Budde K, Matz M, Arns W, Fischereder M, Habicht A, Eisenberger U, Mühlfeld A, Busch M, Wiesener M, Scheffner I, Koch A: (2022) Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial. Transplant Direct. 2022;8(5):
Park J, Bakhtiari M, Popp B, Wiesener M, Bafna V: (2022) Detecting tandem repeat variants in coding regions using code-adVNTR. iScience. 2022;25(8):
Olinger E, Schaeffer C, Kidd K, Elhassan EAE, Cheng Y, Dufour I, Schiano G, Mabillard H, Pasqualetto E, Hofmann P, Fuster DG, Kistler AD, Wilson IJ, Kmoch S, Raymond L, Robert T, Genomics England Research Consortium , Eckardt KU, Bleyer AJ, Köttgen A, Conlon PJ, Wiesener M, Sayer JA, Rampoldi L, Devuyst O: (2022) An intermediate-effect size variant in UMOD confers risk for chronic kidney disease. Proc Natl Acad Sci U S A. 2022;119(33):
Popp B, Ekici AB, Knaup KX, Schneider K, Uebe S, Park J, Bafna V, Meiselbach H, Eckardt KU, Schiffer M, Reis A, Kraus C, Wiesener M: (2022) Prevalence of hereditary tubulointerstitial kidney diseases in the German Chronic Kidney Disease study. Eur J Hum Genet. 2022;30(12): 1413-1422
Arnold ML, Steffen U, Wiesener M, Bach C, Spriewald BM, Lindemann M: (2022) Correlation of Anti-HLA IgA Alloantibodies and Fc Receptor Motives with Kidney Allograft Survival Immuno. 2022;2(2): 372-386
Vanderliek K, Afonso S, Loeschmann I, Wiesener M, Krebs C, Wiech T, Skerka C, Zipfel P: (2022) Monitoring complement biomarkers in C3 glomerulopathy patients with factor H or FHR gene mutations before and after treatment with eculizumab or ravulizumab Mol Immunol. 2022;141(): 201-201
Schwarz H, Popp B, Airik R, Torabi N, Knaup KX, Stoeckert J, Wiech T, Amann K, Reis A, Schiffer M, Wiesener MS, Schueler M: (2022) Biallelic ANKS6 mutations cause late-onset ciliopathy with chronic kidney disease through YAP dysregulation. Hum Mol Genet. 2022;31(9): 1357-1369
Wasielewski E, Lippler S, Knaup KX, Gary R, Aigner M, Kremer A, Pfister F, Amman K, Schiffer M, Mackensen A, Wiesener MS: (2021) BKPYV-SPECIFIC T CELLS REDUCE VIRAL LOAD IN A PRIMARY TUBULAR CELL MODEL Transpl Int. 2021;34 Suppl 2(): 23-24
Bach C, Knaup KX, Herrmann M, Krumbiegel M, Pfister F, Büttner-Herold M, Steffen M, Zecher D, Lopau K, Schneider K, Dieterle A, Amann K, Reis A, Schiffer M, Spriewald BM, Wiesener MS: (2021) A noninvasive diagnostic approach to retrospective donor HLA typing in kidney transplant patients using urine. Transpl Int. 2021;34(7): 1226-1238
Gulluni F, Prever L, Li H, Krafcikova P, Corrado I, Lo WT, Margaria JP, Chen A, De Santis MC, Cnudde SJ, Fogerty J, Yuan A, Massarotti A, Sarijalo NT, Vadas O, Williams RL, Thelen M, Powell DR, Schueler M, Wiesener MS, Balla T, Baris HN, Tiosano D, McDermott BM, Perkins BD, Ghigo A, Martini M, Haucke V, Boura E, Merlo GR, Buchner DA, Hirsch E: (2021) PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation. Science. 2021;374(6573):
Spriewald BM, Herrmann M, Bach C, Knaup KX, Krumbiegel M, Reis A, Schiffer M, Wiesener M: (2020) A NEW DIAGNOSTIC APPROACH TO HLA TESTING IN KIDNEY TRANSPLANT RECIPIENTS USING CULTURED URINE DERIVED TUBULAR CELLS HLA. 2020;95(4): 313-313
Herrmann M, Bach C, Knaup KX, Schiffer M, Spriewald B, Wiesener MS: (2020) A New Diagnostic Approach to HLA Testing in Kidney Transplant Patients Using Renal Epithelial Cells Am J Transplant. 2020;20 Suppl 3(): 704-705
Wiesener A, Knaup KX, Büttner-Herold M, Dieterle A, Stoeckert J, Riedl B, Morath C, Wald A, Vondran F, Braun F, Schödel J, Schueler M, Schiffer M, Amann K, Reis A, Kraus C, Wiesener MS: (2020) Molecular diagnosis of kidney transplant failure based on urine. Am J Transplant. 2020;20(5): 1410-1416
Erger F, Nörling D, Borchert D, Leenen E, Habbig S, Wiesener MS, Bartram MP, Wenzel A, Becker C, Toliat MR, Nürnberg P, Beck BB, Altmüller J: (2020) cfNOMe - A single assay for comprehensive epigenetic analyses of cell-free DNA. Genome Med. 2020;12(1):
Müller HHO, Lücke C, Englbrecht M, Wiesener MS, Siller T, Eckardt KU, Kornhuber J, Maler JM: (2020) Kidney-transplant patients receiving living- or dead-donor organs have similar psychological outcomes (findings from the PI-KT study). Ment Illn. 2020;12(1): 17-22
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK, HERCULES Investigators , Bird R, Fay K, He S, Mason K, Shortt J, Tan P, Breems D, Dierickx D, Gilles A, Lambert C, Clark W, Kassis J, Robinson S, Gumulec J, Hlusi A, Maly J, Mayer J, Benhamou Y, Chantepie S, Hamidou M, Mariotte E, Poullin P, Presne C, Provot F, Savey L, Bommer M, Chemnitz J, Feldkamp T, Fischereder M, Haas C, Hugo C, Petros S, Wanner C, Wiesener M, Boda Z, Reti M, Akria L, Ellis M, Kalish Y, Kirgner I, Nadir Y, Rahimi-Levene N, Spectre G, Di Bona E, Giuffrida G, Sica S, Visani G, Cid J, Goterris Viciedo R, Martin Sanchez J, Pascual Izquierdo C, Valcarcel Ferreiras D, Studt JD, Fijnheer R, te Boekhorst P, Vreugdenhil G, Zwaginga JJ, Aktan M, Arslan O, Kabukcu Hacioglu S, Kaynar L, Sahin F, Sonmez M, Clark A, Dutt T, McDonald V, Antun A, Blinder M, Farland A, Go R, Goodarzi K, Greenberg C, Khawandanah M, Kiss J, Kraut E, Lerner R, Liles D, McCrae K, Pham H, Raval J, Refaai M, Rice L, Rodgers G, Weitz I, Sarode R, Friedman K, Gadisseur A, Hornig F, Kassner S, Mahaffey K, Jilma B: (2019) Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4): 335-346
Schmidt-Lauber C, Jacobi J, Polifka I, Hilgers KF, Wiesener MS: (2019) Suspected colonic cancer turns out to be disseminated tuberculosis in a kidney transplant recipient: A case report. Medicine (Baltimore). 2019;98(36):
Tiosano D, Baris HN, Chen A, Hitzert MM, Schueler M, Gulluni F, Wiesener A, Bergua A, Mory A, Copeland B, Gleeson JG, Rump P, van Meer H, Sival DA, Haucke V, Kriwinsky J, Knaup KX, Reis A, Hauer NN, Hirsch E, Roepman R, Pfundt R, Thiel CT, Wiesener MS, Aslanyan MG, Buchner DA: (2019) Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. PLoS Genet. 2019;15(4):
Schmidt-Lauber C, Büttner-Herold M, Schiffer M, Wiesener MS: (2019) Tuberculous granulomatous interstitial nephritis in a renal allograft. Kidney Int. 2019;96(5):
Popp B, Agaimy A, Kraus C, Knaup KX, Ekici AB, Uebe S, Reis A, Wiesener M, Zweier C: (2019) Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability BMC Cancer. 2019;19():
Vasileiou G, Hoyer J, Thiel CT, Schaefer J, Zapke M, Krumbiegel M, Kraus C, Zweier M, Uebe S, Ekici AB, Schneider M, Wiesener M, Rauch A, Faschingbauer F, Reis A, Zweier C, Popp B: (2019) Prenatal diagnosis of HNF1B-associated renal cysts: Is there a need to differentiate intragenic variants from 17q12 microdeletion syndrome? Prenat Diagn. 2019;39(12): 1136-1147
Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group , Almartine E, Dantal J, Dragun D, Feldkamp T, Hauser IA, Hazzan M, Heyne N, Hugo C, Kamar N, Lang P, Lehner F, Le Meur Y, Lutz J, Merville P, Morelon E, Moulin B, Mousson C, Muehlfeld A, Nashan B, Pisarski P, Rondeau E, Schenker P, Sommerer C, Suwelack B, Thaiss F, Thierry A, Wiesener M, Witzke O: (2019) An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96(1): 231-244
Rudnick RB, Chen Q, Stea ED, Hartmann A, Papac-Milicevic N, Person F, Wiesener M, Binder CJ, Wiech T, Skerka C, Zipfel PF: (2018) FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces. J Immunol. 2018;200(7): 2280-2290
Wenzel A, Altmueller J, Ekici AB, Popp B, Stueber K, Thiele H, Pannes A, Staubach S, Salido E, Nuernberg P, Reinhardt R, Reis A, Rump P, Hanisch FG, Wolf MTF, Wiesener M, Huettel B, Beck BB: (2018) Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations. Sci Rep. 2018;8(1):
Meng X, Grötsch B, Luo Y, Knaup KX, Wiesener MS, Chen XX, Jantsch J, Fillatreau S, Schett G, Bozec A: (2018) Hypoxia-inducible factor-1? is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat Commun. 2018;9(1): 251
Bobka S, Ebert N, Koertvely E, Jacobi J, Wiesener M, Büttner-Herold M, Amann K, Daniel C: (2018) Is Early Complement Activation in Renal Transplantation Associated with Later Graft Outcome? Kidney Blood Press Res. 2018;43(5): 1488-1504
Knaup KX, Hackenbeck T, Popp B, Stoeckert J, Wenzel A, Büttner-Herold M, Pfister F, Schueler M, Seven D, May AM, Halbritter J, Gröne HJ, Reis A, Beck BB, Amann K, Ekici AB, Wiesener MS: (2018) Biallelic Expression of Mucin-1 in Autosomal Dominant Tubulointerstitial Kidney Disease: Implications for Nongenetic Disease Recognition. J Am Soc Nephrol. 2018;29(9): 2298-2309
Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M: (2017) Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2): 304-315
Connor TM, Hoer S, Mallett A, Gale DP, Gomez-Duran A, Posse V, Antrobus R, Moreno P, Sciacovelli M, Frezza C, Duff J, Sheerin NS, Sayer JA, Ashcroft M, Wiesener MS, Hudson G, Gustafsson CM, Chinnery PF, Maxwell PH: (2017) Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genet. 2017;13(3): e1006620
Cremaschi L, von Versen R, Benzing T, Wiesener M, Zink N, Milkovich G, Paivanas T, Gallagher M, Thaiss F: (2017) Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective. Transpl Int. 2017;30(10): 1011-1019
Knaup KX, Guenther R, Stoeckert J, Monti JM, Eckardt KU, Wiesener MS: (2017) HIF is not essential for suppression of experimental tumor growth by mTOR inhibition. J Cancer. 2017;8(10): 1809-1817
Chen Q, Manzke M, Hartmann A, Büttner M, Amann K, Pauly D, Wiesener M, Skerka C, Zipfel PF: (2016) Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces. J Am Soc Nephrol. 2016;27(5): 1413-25
Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K: (2016) Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int. 2016;29(11): 1184-1195
Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C: (2016) Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388(10063): 3006-3016
Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU: (2015) Identification of Cyclin D1 and OtherNovel Targets for the von Hippel-Lindau Tumor Suppressor Gene by Expression Array Analysis and Investigation of Cyclin D1 Genotype as a Modifier in von Hippel-Lindau Disease (vol 62, pg 3803, 2002) Cancer Res. 2015;75(18): 3993-3993
Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst O: (2015) Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management-A KDIGO consensus report. Kidney Int. 2015;88(4): 676-83
Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE: (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7): 1474-8
Jobst-Schwan T, Pannes A, Schlingmann KP, Eckardt KU, Beck BB, Wiesener MS: (2015) Discordant Clinical Course of Vitamin-D-Hydroxylase (CYP24A1) Associated Hypercalcemia in Two Adult Brothers With Nephrocalcinosis. Kidney Blood Press Res. 2015;40(5): 443-51
Schley G, Scholz H, Kraus A, Hackenbeck T, Klanke B, Willam C, Wiesener MS, Heinze E, Burzlaff N, Eckardt KU, Buchholz B: (2015) Hypoxia inhibits nephrogenesis through paracrine Vegfa despite the ability to enhance tubulogenesis. Kidney Int. 2015;88(6): 1283-1292
Müller HH, Englbrecht M, Wiesener MS, Titze S, Heller K, Groemer TW, Schett G, Eckardt KU, Kornhuber J, Maler JM: (2015) Depression, Anxiety, Resilience and Coping Pre and Post Kidney Transplantation - Initial Findings from the Psychiatric Impairments in Kidney Transplantation (PI-KT)-Study. PLoS ONE. 2015;10(11): e0140706
Arnold ML, Fuernrohr BG, Weiß KM, Harre U, Wiesener MS, Spriewald BM: (2015) Association of a coding polymorphism in Fc gamma receptor 2A and graft survival in re-transplant candidates. Hum Immunol. 2015;76(10): 759-64
Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF: (2014) Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest. 2014;124(1): 145-55
Ekici AB, Hackenbeck T, Morinière V, Pannes A, Buettner M, Uebe S, Janka R, Wiesener A, Hermann I, Grupp S, Hornberger M, Huber TB, Isbel N, Mangos G, McGinn S, Soreth-Rieke D, Beck BB, Uder M, Amann K, Antignac C, Reis A, Eckardt KU, Wiesener MS: (2014) Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. Kidney Int. 2014;86(3): 589-99
Knaup KX, Monti J, Hackenbeck T, Jobst-Schwan T, Klanke B, Schietke RE, Wacker I, Behrens J, Amann K, Eckardt KU, Warnecke C, Wiesener MS: (2014) Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro. Mol Carcinog. 2014;53(12): 970-8
Jobst-Schwan T, Knaup KX, Nielsen R, Hackenbeck T, Büttner-Herold M, Lechler P, Kroening S, Goppelt-Struebe M, Schloetzer-Schrehardt U, Fuernrohr BG, Voll RE, Amann K, Eckardt KU, Christensen EI, Wiesener MS: (2013) Renal uptake of the antiapoptotic protein survivin is mediated by megalin at the apical membrane of the proximal tubule. Am J Physiol Renal Physiol. 2013;305(5): F734-44
Schietke RE, Hackenbeck T, Tran M, Günther R, Klanke B, Warnecke CL, Knaup KX, Shukla D, Rosenberger C, Koesters R, Bachmann S, Betz P, Schley G, Schödel J, Willam C, Winkler T, Amann K, Eckardt KU, Maxwell P, Wiesener MS: (2012) Renal Tubular HIF-2? Expression Requires VHL Inactivation and Causes Fibrosis and Cysts. PLoS ONE. 2012;7(1): e31034
Hackenbeck T, Huber R, Schietke R, Knaup KX, Monti J, Wu X, Klanke B, Frey B, Gaipl U, Wullich B, Ferbus D, Goubin G, Warnecke C, Eckardt KU, Wiesener MS: (2011) The GTPase RAB20 is a HIF target with mitochondrial localization mediating apoptosis in hypoxia. BBA - MOL CELL RES. 2011;1813(1): 1-13
Schley G, Klanke B, Schödel J, Forstreuter F, Shukla D, Kurtz A, Amann K, Wiesener MS, Rosen S, Eckardt KU, Maxwell PH, Willam C: (2011) Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol. 2011;22(11): 2004-15
Schietke RE, Warnecke C, Wacker I, Schödel J, Mole DR, Câmpean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt KU, Wiesener MS: (2010) The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem. 2010;285(9): 6658-69
Gimm T, Wiese M, Teschemacher B, Deggerich A, Schödel J, Knaup KX, Hackenbeck T, Hellerbrand C, Amann K, Wiesener MS, Höning S, Eckardt KU, Warnecke C: (2010) Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. FASEB J. 2010;24(11): 4443-58
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU: (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12): 2151-6
Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS, Warnecke C, Eckardt KU, Wiesener MS: (2009) Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability. Mol Cancer Res. 2009;7(1): 88-98
Wacker I, Sachs M, Knaup K, Wiesener M, Weiske J, Huber O, Akçetin Z, Behrens J: (2009) Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor. Mol Cell Biol. 2009;29(7): 1707-18
Hackenbeck T, Knaup KX, Schietke R, Schödel J, Willam C, Wu X, Warnecke C, Eckardt KU, Wiesener MS: (2009) HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia. Cell Cycle. 2009;8(9): 1386-95
Schödel J, Klanke B, Weidemann A, Buchholz B, Bernhardt W, Bertog M, Amann K, Korbmacher C, Wiesener M, Warnecke C, Kurtz A, Eckardt KU, Willam C: (2009) HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury. Am J Pathol. 2009;174(5): 1663-74
Kroening S, Neubauer E, Wessel J, Wiesener M, Goppelt-Struebe M: (2009) Hypoxia interferes with connective tissue growth factor (CTGF) gene expression in human proximal tubular cell lines. Nephrol Dial Transplant. 2009;24(11): 3319-25
Wiesener MS, Maxwell PH, Eckardt KU: (2009) Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression. J Mol Med. 2009;87(9): 871-7
Tanaka T, Wiesener MS, Bernhardt W, Eckardt KU, Warnecke C: (2009) The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J. 2009;424(1): 143-51
Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Câmpean V, Schödel J, Reisenbuechler A, Klaus S, Arend M, Flippin L, Willam C, Wiesener MS, Yard B, Warnecke C, Eckardt KU: (2009) Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci U S A. 2009;106(50): 21276-81
Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ, Maher ER: (2009) Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res. 2009;29(11): 4337-43
Weidemann A, Bernhardt WM, Klanke B, Daniel C, Buchholz B, Câmpean V, Amann K, Warnecke C, Wiesener MS, Eckardt KU, Willam C: (2008) HIF activation protects from acute kidney injury. J Am Soc Nephrol. 2008;19(3): 486-94
Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG, Volke M, Gläsner J, Warnecke C, Wiesener MS, Eckardt KU, Steinkasserer A, Hensel M, Willam C: (2008) Hypoxia and Hypoxia-Inducible Factor-1{alpha} Modulate Lipopolysaccharide-Induced Dendritic Cell Activation and Function. J Immunol. 2008;180(7): 4697-705
Warnecke C, Weidemann A, Volke M, Schietke R, Wu X, Knaup KX, Hackenbeck T, Bernhardt W, Willam C, Eckardt KU, Wiesener MS: (2008) The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res. 2008;314(10): 2016-27
Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, Wiesener M, Eckardt KU, Koch CJ, Ellies LG, Haddad G, Haase VH, Simon MC, Poellinger L, Powell FL, Johnson RS: (2008) Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell. 2008;133(2): 223-34
Gelse K, Mühle C, Knaup K, Swoboda B, Wiesener M, Hennig F, Olk A, Schneider H: (2008) Chondrogenic differentiation of growth factor-stimulated precursor cells in cartilage repair tissue is associated with increased HIF-1alpha activity. Osteoarthritis Cartilage. 2008;16(12): 1457-65
Gelse K, Pfander D, Obier S, Knaup KX, Wiesener M, Hennig FF, Swoboda B: (2008) Role of hypoxia-inducible factor 1 alpha in the integrity of articular cartilage in murine knee joints. Arthritis Res Ther. 2008;10(5): R111
Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, Eckardt KU, Warnecke C: (2008) Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J. 2008;409(1): 233-42
Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Wiesener MS, Richards FM, Johnson CM, Latif F, Maher ER: (2007) Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene. 2007;26(11): 1661-72
Foster RE, Abdulrahman M, Morris MR, Prigmore E, Gribble S, Ng B, Gentle D, Ready S, Weston PM, Wiesener MS, Kishida T, Yao M, Davison V, Barbero JL, Chu C, Carter NP, Latif F, Maher ER: (2007) Characterization of a 3;6 translocation associated with renal cell carcinoma. Genes Chromosomes Cancer. 2007;46(4): 311-7
Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Câmpean V, Ong AC, Willam C, Gretz N, Eckardt KU: (2007) Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol. 2007;170(3): 830-42
Eckardt KU, Bernhardt W, Willam C, Wiesener M: (2007) Hypoxia-inducible transcription factors and their role in renal disease. Semin Nephrol. 2007;27(3): 363-72
Wiesener MS, Münchenhagen P, Glaser M, Sobottka BA, Knaup KX, Jozefowski K, Jürgensen JS, Roigas J, Warnecke C, Gröne HJ, Maxwell PH, Willam C, Eckardt KU: (2007) Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer. 2007;121(11): 2434-42
Lechler P, Wu X, Bernhardt W, Câmpean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Willam C, Eckardt KU, Rödel F, Wiesener MS: (2007) The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol. 2007;171(5): 1483-98
Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU: (2007) Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol. 2007;435(): 219-45
Willam C, Warnecke C, Schefold JC, Kügler J, Koehne P, Frei U, Wiesener M, Eckardt KU: (2006) Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch. 2006;451(4): 534-43
Rosenberger C, Rosen S, Shina A, Bernhardt W, Wiesener MS, Frei U, Eckardt KU, Heyman SN: (2006) Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int. 2006;70(1): 60-70
Bernhardt WM, Câmpean V, Kany S, Jürgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Günzler V, Amann K, Willam C, Wiesener MS, Eckardt KU: (2006) Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006;17(7): 1970-8
Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W, Wiesener M, Ratcliffe PJ, Eckardt KU, Pugh CW: (2006) HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41(1): 68-77
Bernhardt WM, Schmitt R, Rosenberger C, Münchenhagen PM, Gröne HJ, Frei U, Warnecke C, Bachmann S, Wiesener MS, Willam C, Eckardt KU: (2006) Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int. 2006;69(1): 114-22
Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C: (2005) Role of hypoxia in the pathogenesis of renal disease Kidney Int. 2005;68 Suppl. (): 46-51
Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C: (2005) Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl. 2005;(99): S46-51
Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER: (2005) Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65(11): 4598-606
Knaup K, Weidemann A, Jozefowski K, Jürgensen JS, Eckardt KU, Wiesener M: (2005) Inhibition of mTOR attenuates hypoxic gene regulation in renal cells Nephrol Dial Transplant. 2005;20 Suppl.(): V16-V17
Bernhardt WM, Kany S, Câmpean V, Jürgensen JS, Weidemann A, Warnecke C, Willam C, Frei U, Amann K, Wiesener MS, Eckardt KU: (2005) Preconditional induction of HIF by carbon monoxide ameliorates ischemic acute renal failure Nephrol Dial Transplant. 2005;20 Suppl.(): V54-V54
Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU: (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 2004;18(12): 1462-4
Jürgensen JS, Rosenberger C, Wiesener MS, Warnecke C, Hörstrup JH, Gräfe M, Philipp S, Griethe W, Maxwell PH, Frei U, Bachmann S, Willenbrock R, Eckardt KU: (2004) Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J. 2004;18(12): 1415-7
Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU: (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003;17(2): 271-3
Warnecke C, Griethe W, Weidemann A, Jürgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, Eckardt KU: (2003) Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 2003;17(9): 1186-8
Eckardt KU, Rosenberger C, Jürgensen JS, Wiesener MS: (2003) Role of hypoxia in the pathogenesis of renal disease. Blood Purif. 2003;21(3): 253-7
Rosenberger C, Griethe W, Gruber G, Wiesener M, Frei U, Bachmann S, Eckardt KU: (2003) Cellular responses to hypoxia after renal segmental infarction. Kidney Int. 2003;64(3): 874-86
Wiesener MS, Eckardt KU: (2002) Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing. Nephrol Dial Transplant. 2002;17(3): 356-9
Wiesener MS, Seyfarth M, Warnecke C, Jürgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU: (2002) Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99(10): 3562-5
Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU: (2002) Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13(7): 1721-32
Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER: (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002;62(13): 3803-11
Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU: (2001) Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001;61(13): 5215-22

Sprechstunden

Nierenerkrankungen (genetisch)

Sprechstunde für genetische Nierenerkrankungen unklarer Genese

Spezialsprechstunde

Prof. Dr. med. Michael Wiesener

Zeiten
nach Vereinbarung

Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen

Raum
D 0 723-1

Kontakt für Terminvergabe
Terminvergabe nur nach Absprache

Hochschulambulanz
Montag bis Freitag
11.00 - 15.00 Uhr
Telefon: 09131 85-32566
Fax: 09131 85-33431

Hinweis

Bei dieser Sprechstunde steht die Diagnostik im Vordergrund.

Mitzubringen

Versicherungsnachweis (Krankenkassenkarte)
Zuweisung
Medikamentenliste
Befundberichte von Ihrem Facharzt (falls vorhanden)

Nierentransplantationsnachsorge

Spezialsprechstunde

Prof. Dr. med. Michael Wiesener
Dr. med. Mirian Opgenoorth

Zeiten
nach Vereinbarung

Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen

Raum
D 0 723-1

Kontakt für Terminvergabe
Terminvergabe nur nach Absprache

Hochschulambulanz
Montag bis Freitag
11.00 - 15.00 Uhr
Telefon: 09131 85-32566
Fax: 09131 85-33431

Hinweis

Patienten nach erfolgter Nierentransplantation werden in dieser Sprechstunde umfassend betreut. Dabei kümmern wir uns auch intensiv um Immunsuppression und die Transplantatfunktion.

Mitzubringen

Versicherungsnachweis (Krankenkassenkarte)
Zuweisung
Medikamentenliste
Befundberichte von Ihrem Facharzt (falls vorhanden)

Allgemeinsprechstunde

Nephrologie

Prof. Dr. med. Michael Wiesener
Dr. med. Kristina Rodionova
Dr. med. Anne Dieterle

Zeiten
nach Vereinbarung

Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen

Raum
D 0 723-1

Kontakt für Terminvergabe
Terminvergabe nur nach Absprache

Hochschulambulanz
Montag bis Freitag
11.00 - 15.00 Uhr
Telefon: 09131 85-32566
Fax: 09131 85-33431

Hinweis

In dieser Sprechstunde werden Patienten mit komplexer und schwerwiegender chronischer Niereninsuffizienz betreut in Zusammenarbeit mit den niedergelassenen Nephrologen.

Mitzubringen

Versicherungsnachweis (Krankenkassenkarte)
Zuweisung
Medikamentenliste
Befundberichte von Ihrem Facharzt (falls vorhanden)

Pankreastransplantationsnachsorge

Bauchspeicheldrüse

Spezialsprechstunde

Prof. Dr. med. Michael Wiesener
Dr. med. Mirian Opgenoorth

Zeiten
Montag - Freitag: ab 7.30 Uhr

Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen

Raum
D 0 723-1

Kontakt für Terminvergabe
Terminvergabe nur nach Absprache

Hochschulambulanz

Montag bis Freitag
11.00 - 15.00 Uhr
Telefon: 09131 85-32566
Fax: 09131 85-33431

Hinweis

Patienten nach erfolgter kombinierter Pankreas-Nierentransplantation werden in dieser Sprechstunde umfassend betreut. Dabei kümmern wir uns auch intensiv um Immunsuppression und die Transplantatfunktion.

Mitzubringen

Versicherungsnachweis (Krankenkassenkarte)
Zuweisung
Medikamentenliste
Befundberichte von Ihrem Facharzt (falls vorhanden)

zur Kontaktliste

Schriftgröße anpassen

Prof. Dr. med. Michael Wiesener